Injectable Biodegradable Silica Depot for Controlled Subcutaneous Delivery of Antisense Oligonucleotides with beyond Monthly Administration-Reference-Cited by-同舟云学术

Injectable Biodegradable Silica Depot for Controlled Subcutaneous Delivery of Antisense Oligonucleotides with beyond Monthly Administration

Published:2023-12-21 Issue:1 Volume:21 Page:143-151
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

McGowan Asmaa¹,Gennemark Peter²³,Akieh-Pirkanniemi Marceline¹,Wirman Linda¹,Davies Nigel⁴^ORCID,Elebring Marie²,Tivesten Anna⁵,Strimfors Marie⁶,Hölttä Mikko²,Söderberg Magnus⁷,Berntsson Veronica⁴,Balas Daniela⁴,Koskinen Mika¹,Leino Lasse¹,Abrahmsén-Alami Susanna⁸^ORCID

Affiliation:

1. DelSiTech Ltd., PharmaCity, Itäinen Pitkäkatu 4 B, 20520 Turku, Finland

2. Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden

3. Department of Biomedical Engineering, Linköping University, Linköping 581 83, Sweden

4. Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden

5. CVRM CMC Projects, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden

6. Bioscience metabolism, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden

7. Pathology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden

8. Sustainable Innovation & Transformational Excellence, Pharmaceutical Technology & Development, Operations, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden

Funder

AstraZeneca

DelsiTech

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.3c00663

Reference24 articles.

1. The current landscape of nucleic acid therapeutics

2. Chemistry, structure and function of approved oligonucleotide therapeutics

3. Considerations for the Terminal Sterilization of Oligonucleotide Drug Products

4. New and Future Parenteral Therapies for the Management of Lipid Disorders

5. Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience